Corinne Noyes - Jan 31, 2023 Form 4 Insider Report for Lyra Therapeutics, Inc. (LYRA)

Role
SVP of Commercial Strategy and Market Development
Signature
/s/ Jason Cavalier, Attorney-in-Fact for Corinne Noyes
Stock symbol
LYRA
Transactions as of
Jan 31, 2023
Transactions value $
$0
Form type
4
Date filed
2/2/2023, 04:12 PM
Previous filing
Feb 15, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LYRA Common Stock Award $0 +36.7K $0.00 36.7K Jan 31, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LYRA Stock Option Award $0 +55K $0.00 55K Jan 31, 2023 Common Stock 55K $2.85 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in four (4) equal annual installments on the first four anniversaries of the grant date such that the RSUs will fully vest on January 31, 2027.
F2 This option vests and becomes exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following January 31, 2023.

Remarks:

SVP of Commercial Strategy and Market Development